Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.36 Average Target Price from Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, two have given a buy recommendation and two have […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, two have given a buy recommendation and two have […]
